Randomized phase II trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO …

E Fokas, M Allgäuer, B Polat, G Klautke… - Journal of Clinical …, 2019 - ascopubs.org
PURPOSE Total neoadjuvant therapy is a new paradigm for rectal cancer treatment. Optimal
scheduling of preoperative chemoradiotherapy (CRT) and chemotherapy remains to be …

Total neoadjuvant therapy versus standard therapy in locally advanced rectal cancer: a systematic review and meta-analysis of 15 trials

X Zhang, S Ma, Y Guo, Y Luo, L Li - PLoS One, 2022 - journals.plos.org
Background Neoadjuvant chemoradiotherapy (nCRT) before total mesorectal excision
(TME) and followed systemic chemotherapy is widely accepted as the standard therapy for …

Tyrosine kinase inhibitors and their unique therapeutic potentialities to combat cancer

Y Zhao, M Bilal, A Raza, MI Khan, S Mehmood… - International journal of …, 2021 - Elsevier
Cancer is one of the leading causes of death with a mortality rate of 12%. Although
significant progress has been achieved in cancer research, the effective treatment of cancer …

An experimental strategy unveiling exosomal microRNAs 486-5p, 181a-5p and 30d-5p from hypoxic tumour cells as circulating indicators of high-risk rectal cancer

T Bjørnetrø, KR Redalen, S Meltzer… - Journal of …, 2019 - Taylor & Francis
Tumour hypoxia contributes to poor treatment outcome in locally advanced rectal cancer
(LARC) and circulating extracellular vesicles (EVs) as potential biomarkers of tumour …

LncRNA PART1 regulates colorectal cancer via targeting miR-150-5p/miR-520h/CTNNB1 and activating Wnt/β-catenin pathway

T Zhou, L Wu, N Ma, F Tang, Z Zong, S Chen - The International Journal of …, 2020 - Elsevier
Numerous studies have reported that lncRNAs could play a significant role in
carcinogenesis. PART1, as an identified lncRNA, was an oncogene in several cancers …

Alliance A022104/NRG-GI010: The Janus Rectal Cancer Trial: a randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding …

JA Alvarez, Q Shi, A Dasari, J Garcia-Aguilar, H Sanoff… - BMC cancer, 2024 - Springer
Background Recent data have demonstrated that in locally advanced rectal cancer (LARC),
a total neoadjuvant therapy (TNT) approach improves compliance with chemotherapy and …

Molecular and kinetic analyses of circulating tumor cells as predictive markers of treatment response in locally advanced rectal cancer patients

BC Troncarelli Flores, V Souza e Silva, E Ali Abdallah… - Cells, 2019 - mdpi.com
Neoadjuvant chemoradiation (NCRT) followed by total mesorectal excision is the standard
treatment for locally advanced rectal cancer (LARC). To justify a non-surgical approach …

Outcomes of Locally Advanced Rectal Cancer Patients Treated with Total Neoadjuvant Treatment: A Meta-Anaysis of Randomized Controlled Trials

M Gabbani, C Giorgi, G Napoli, U Tebano… - Clinical Colorectal …, 2022 - Elsevier
Abstract Background & Aims Determining outcomes using the total neoadjuvant therapy
(TNT) in patients with local advanced rectal cancer is important for stratifying patients …

Predicting prognosis according to preoperative chemotherapy response in patients with locally advanced lower rectal cancer

T Shiraishi, T Sasaki, K Ikeda, Y Tsukada, Y Nishizawa… - BMC cancer, 2019 - Springer
Background Neoadjuvant chemoradiotherapy is regarded as the standard of treatment for
locally advanced lower rectal cancer, although some of these cases are systemic, and …

Advances in the treatment of locally advanced rectal cancer

F Ali, A Keshinro, MR Weiser - Annals of gastroenterological …, 2021 - Wiley Online Library
Locally advanced rectal cancer requires multidisciplinary care. In the United States, most
patients are treated with neoadjuvant chemoradiation delivered over 25‐28 days, total …